This week, six Federal Circuit panels will hear oral argument on at various venues in New York City. Two of today’s oral arguments are in biosimilar cases that we have been closely following on this blog.
First, at 10:00 AM, a panel will hear oral argument at the U.S. Court of International Trade in downtown Manhattan on Janssen’s appeals from (1) the district court’s partial final judgment of invalidity of Janssen’s ’471 patent based on a finding of obviousness-type double patenting in the Janssen v. Celltrion BPCIA litigation concerning Celltrion’s Inflectra® (infliximab-dyyb) biosimilar product, and (2) an ex parte reexamination ruling by the USPTO that the ’471 patent’s claims are unpatentable for obviousness-type double patenting.
Second, at 2:00 PM, a panel will hear oral argument at Cardozo Law School on Amgen’s appeal from the district court’s judgment of non-infringement in favor of Apotex regarding Apotex’s proposed biosimilar of Neulasta (pegfilgrastim).
Check back here at Big Molecule Watch later today for our reports on these oral arguments.